Last reviewed · How we verify
melphalan, thalidomide and dexamethasone — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
melphalan, thalidomide and dexamethasone (melphalan, thalidomide and dexamethasone) — FDA Office of Orphan Products Development.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| melphalan, thalidomide and dexamethasone TARGET | melphalan, thalidomide and dexamethasone | FDA Office of Orphan Products Development | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- melphalan, thalidomide and dexamethasone CI watch — RSS
- melphalan, thalidomide and dexamethasone CI watch — Atom
- melphalan, thalidomide and dexamethasone CI watch — JSON
- melphalan, thalidomide and dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). melphalan, thalidomide and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/melphalan-thalidomide-and-dexamethasone. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing